Evaluation of serum alpha-1B glycoprotein and C-reactive protein levels as biomarkers of canine benign prostatic hyperplasia
5
Issued Date
2025-06-01
Resource Type
ISSN
09728988
eISSN
22310916
Scopus ID
2-s2.0-105015420243
Journal Title
Veterinary World
Volume
18
Issue
6
Start Page
1540
End Page
1548
Rights Holder(s)
SCOPUS
Bibliographic Citation
Veterinary World Vol.18 No.6 (2025) , 1540-1548
Suggested Citation
Wongbandue G., Ploypetch S., Pruksakitcharoen P., Udomrit K., Nujan K., Seekhumtae R., Thubthim T., Prapaiwan N. Evaluation of serum alpha-1B glycoprotein and C-reactive protein levels as biomarkers of canine benign prostatic hyperplasia. Veterinary World Vol.18 No.6 (2025) , 1540-1548. 1548. doi:10.14202/vetworld.2025.1540-1548 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112086
Title
Evaluation of serum alpha-1B glycoprotein and C-reactive protein levels as biomarkers of canine benign prostatic hyperplasia
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background and Aim: Benign prostatic hyperplasia (BPH) is a prevalent disorder in aging male dogs, characterized by prostate enlargement secondary to hormonal dysregulation and chronic inflammation. Identifying non-invasive biomarkers is crucial for improving diagnosis and monitoring therapeutic interventions. This study aimed to evaluate serum alpha-1B glycoprotein (A1BG) and C-reactive protein (CRP) concentrations in dogs with BPH before and after castration, to assess their diagnostic and prognostic utility. Materials and Methods: A total of 20 male dogs were assigned to two groups: healthy controls (n = 10) and BPH-affected dogs (n = 10). Blood samples were collected from controls and the BPH group at diagnosis and 1 month post-castration. Serum A1BG and CRP concentrations were measured using enzyme-linked immunosorbent assay and fluorescence immunoassay, respectively. Prostatic volume (PV) was evaluated ultrasonographically. Results: Dogs with BPH demonstrated significantly lower serum A1BG concentrations before castration compared to healthy controls (p < 0.01) and post-castration (p < 0.01). Post-castration A1BG levels were comparable to controls, suggesting biochemical normalization. Serum CRP concentrations remained within the normal range (<30 mg/L) across all groups and showed no significant differences. A significant negative correlation was observed between age and A1BG concentration in the pre-castration BPH group (r = -0.74, p = 0.02). Castration resulted in a marked reduction in PV, consistent with therapeutic response. Conclusion: Serum A1BG demonstrated potential as a sensitive biomarker for the diagnosis and therapeutic monitoring of canine BPH, in contrast to CRP, which exhibited limited diagnostic value. Normalization of A1BG levels post-castration supports its role in reflecting disease resolution. Integrating A1BG assessment into veterinary diagnostic workflows could enhance early detection, monitoring, and management strategies for BPH, offering a non-invasive and clinically informative approach. Further longitudinal studies with larger cohorts are warranted to validate these findings and explore long-term biomarker dynamics.